Avidity Biosciences stock surges on expansion of pipeline targeting rare genetic cardiomyopathies and improvements in siRNA ...
Barclays analyst Gena Wang maintained a Buy rating on Avidity Biosciences (RNA – Research Report) today and set a price target of $63.00.
Keay Nakae’s rating is based on Avidity Biosciences’ strategic focus on genetically validated targets for cardiomyopathies using their proprietary antibody oligonucleotide conjugate (AOC) technology.
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide ...
Avidity Biosciences, Inc. (NASDAQ ... The company's proprietary antibody-oligonucleotide conjugate (AOC) platform has garnered significant attention from investors and analysts alike, as it ...
Avidity Biosciences, Inc. (NASDAQ:RNA) has emerged as a prominent player in the biotechnology sector, focusing on developing innovative RNA therapies for muscle-related indications. The company's ...
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™),... ByInvesting ...
Investor's Business Daily on MSN5d
Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' NewsShares of Avidity Biosciences surged to a record high Wednesday after the company showed its hand in the cardiovascular space — a first for the company's RNA platform. Please watch the video at ...
Just a few weeks after Avidity Biosciences made a stir with new data ... to nearly $47 when the data was announced. Del-zota is an antibody-oligonucleotide conjugate (AOC), which uses an anti ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback